Market Place
Sourcing Support
Voydeya approved in the EU as add-on treatment to ravulizumab
23 Apr 2024 //
PRESS RELEASE
Onco360 Has Selected as the Sole National Specialty Pharmacy Partner for Voydeya
08 Apr 2024 //
GLOBENEWSWIRE
VOYDEYA™ Approved in The US & Ravulizumab or Eculizumab for the Rare Disease
01 Apr 2024 //
BUSINESSWIRE
FDA clears AZ’s new PNH therapy Voydeya
01 Apr 2024 //
PRESS RELEASE
Voydeya recommended for approval in the EU by CHMP
26 Feb 2024 //
PRESS RELEASE
AZ`s newest PNH med Voydeya approved in Japan
20 Jan 2024 //
FIERCE PHARMA
AstraZeneca shows longer term benefits of next-gen PNH drug
12 Dec 2023 //
FIERCE BIOTECH
PIII trial data showed danicopan as add-on to ULTOMIRIS sustained improvements
10 Dec 2023 //
BUSINESSWIRE
Danicopan as add-on to Ultomiris or Soliris improved haemoglobin levels
09 Jun 2023 //
PRESS RELEASE
Danicopan Add-On to ULTOMIRIS or SOLIRIS Met Primary Endpoint in ALPHA PIII
16 Sep 2022 //
BUSINESSWIRE
Danicopan (ALXN2040) Add-On to ULTOMIRIS® or SOLIRIS® (eculizumab)
16 Sep 2022 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.